氟哌噻吨美利曲辛联合质子泵抑制剂对上腹痛综合征患者的影响

Effect of Flupentixol and Melitracen Combined with Proton Pump Inhibitor on Epigastric Pain Syndrome

背景:功能性消化不良的亚型上腹痛综合征(EPS)临床常见,严重影响患者的生活质量。目的:观察氟哌噻吨美利曲辛联合质子泵抑制剂治疗EPS患者的疗效,以及对患者心理状态和睡眠的影响。方法:选取2013年1月-2014年6月武汉市黄陂区人民医院118例EPS患者,随机分为对照组和观察组。对照组给予埃索美拉唑20 mg,每天1次;观察组在此基础上给予氟哌噻吨美利曲辛10.5 mg bid,两组疗程均为8周。比较两组治疗前后患者的心理状态、睡眠质量和临床疗效。结果:治疗第4、8周末,两组患者焦虑、抑郁、睡眠质量和临床症状较治疗前均明显改善(P<0.05),且观察组焦虑、抑郁和临床症状的改善程度又优于对照组(P<0.05)。观察组的治疗有效率显著高于对照组(94.9%对79.7%,P<0.05)。两组均未发生严重不良反应。结论:氟哌噻吨美利曲辛联合埃索美拉唑可有效改善EPS患者的焦虑和抑郁情绪,提高临床疗效。

Background： Epigastric pain syndrome （EPS） , a subtype of functional dyspepsia, is commonly seen in clinical practice, and severely affects patients＇ quality of life. Aims： To observe the therapeutic efficacy of flupentixol and melitracen combined with proton pump inhibitor on EPS and its influence on psychological status and sleep quality. Methods： A total of 118 EPS patients from Jan. 2013 to June 2014 at Huangpi District People＇s Hospital were enrolled, and were randomly divided into observation group and control group. Patients in control group were given esomeprazole 20 mg/d, while patients in observation group were given flupentixol and melitracen 10. 5 mg bid in addition to esomeprazole, the treatment course were both for 8 weeks. Psychological status, quality of sleep and clinical therapeutic efficacy were compared between the two groups. Results： Four or 8 weeks after the treatment, anxiety, depression, sleep quality and clinical symptom were significantly ameliorated than before treatment in both two groups （ P 〈 0.05 ）, while anxiety, depression and clinical symptom in observation group were significantly better than those in control group （P 〈 0.05）. Therapeutic efficacy in observation group was significantly higher than that in control group （94.9% vs. 79.7% , P 〈 0. 05 ）. No severe adverse reactions were found in both two groups. Conclusions： Flupentixol and melitracen combined with esomeprazale can effectively ameliorate anxiety and depression, and improve the therapeutic efficacy in EPS patients.